CD274 and melanoma: Approval for retrospective data collection, review, and publication for anti-PD(L)1 treated melanoma patients was obtained from the University of Pittsburgh Cancer Institute (UPCI) Institutional Review Board (IRB) (IRB number PRO18080253).